• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NGM

NGM

NGM Biopharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.54

-0.02 (-1.28%)

Company Profile

CEO

David J. Woodhouse

IPO Date

2019-04-04

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.56

Prev. Close

$1.56

Day Low

$1.54

Day High

$1.57

52W Low

$0.60

52W High

$4.69

Market Cap

$0.13B

Volume

2.21M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

19.9%

Avg Negative

57.2%

Avg Neutral

22.9%

News Feed

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

GlobeNewsWire·7/1/2021·↑ positive

NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?

Zacks Investment Research·6/3/2021·↑ positive

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile Corp·5/31/2021·↓ negative

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile Corp·5/27/2021·↓ negative

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

PRNewsWire·5/26/2021·↓ negative

Why NGM Biopharmaceuticals Dived by 41% on Monday

The Motley Fool·5/24/2021·↓ negative

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire·5/24/2021·↓ negative

Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study

Benzinga·5/24/2021·↓ negative

NGM Stock Price: Over 40% Decrease Pre-Market Explanation

Pulse2·5/24/2021·↓ negative

NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

GlobeNewsWire·5/24/2021·↑ positive